Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy
Ying Shen, Jie Liu, Baiyan Wang, et al.
Current Research in Translational Medicine (2023) Vol. 71, Iss. 2, pp. 103378-103378
Closed Access | Times Cited: 11

Showing 11 citing articles:

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 53
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Aina Oliver‐Caldés, Marta Español‐Rego, Aintzane Zabaleta, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2085-2096
Closed Access | Times Cited: 7
Predictive Role of Soluble B‐Cell Maturation Antigen in Short‐Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study
Laura Caponi, Maria Livia Del Giudice, Alice Botti, et al.
Journal of Clinical Laboratory Analysis (2025)
Open Access
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling
Rahul Banerjee, Kara I. Cicero, Sarah S. Lee, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
Targeting BCMA in multiple myeloma: designs, challenges, and future directions
Yi Hu, Yuetao Xie, Xiaodong Wang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access
Soluble B‐cell maturation antigen in multiple myeloma
Bruno Almeida Costa, Ricardo J. Ortiz, Alexander M. Lesokhin, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 727-738
Closed Access | Times Cited: 2
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma
Umair Munawar, Johanna Theuersbacher, Maximilian Steinhardt, et al.
Haematologica (2024)
Open Access | Times Cited: 2
Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma
Pei Guo, Yun Wang, Haiyan He, et al.
Clinical & Experimental Immunology (2024) Vol. 217, Iss. 3, pp. 221-232
Closed Access | Times Cited: 1
Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies
Kevin G. Shim, Rafaël Fonseca
Cancers (2024) Vol. 16, Iss. 19, pp. 3288-3288
Open Access | Times Cited: 1
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features
Belén Sierro-Martínez, Virginia Escamilla Gómez, Laura Pérez-Ortega, et al.
Cellular Oncology (2024) Vol. 48, Iss. 1, pp. 219-237
Open Access
Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma
Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, et al.
eJHaem (2024) Vol. 6, Iss. 1
Closed Access
Page 1

Scroll to top